Quick reference guide to apixaban

Vascular Health and Risk Management

Volumn 13, Issue , 2017, Pages 263-267

  Hurst, Katherine Victoria ^a   O’Callaghan, John Matthew ^a   Handa, Ashok ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apixaban; Stroke management; Venous thromboembolism

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; RISK FACTOR; STROKE;

ADMINISTRATION, ORAL; BLOOD COAGULATION; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 85024113279     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S121944     Document Type: Review

References (24)

1. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-1872.
2. Flaker G, Ezekowitz M, Yusuf S, et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (randomized evaluation of long-term anticoagulation therapy) study. J Am Coll Cardiol. 2012;59(9):854-855.
3. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130(2):138-146.
4. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
5. Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013;34(31):2464-2471.
6. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429-435.
7. Hurst K, Lee R, Handa A. Quick reference guide to the new oral anticoagulants. J Vasc Surg. 2016;63(6):1653-1657.
8. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-953.
9. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
10. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141-2147.
11. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
12. NICE [webpage on the Internet]. Venous thromboembolism in adults: reducing the risk in hospital. 2010. Available from https://www.nice.org.uk/guidance/qs3. Accessed June 13, 2017.
13. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-2498.
14. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-815.
15. Mandernach MW, Beyth RJ, Rajasekhar A. Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. Ther Clin Risk Manag. 2015;11:1273-1282.
16. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835-1846.
17. Idarucizumab (praxbind) - an antidote for dabigatran. Med Lett Drugs Ther. 2015;57(1482):157-158.
18. Keeling D, Cotter F. Management of bleeding in patients taking FXa and FIIa inhibitors. Br J Haematol. 2013;160(1):1-2.
19. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
20. Büller HR, Prins MH, Lensin AW, et al; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.
21. Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3(2):e000521.
22. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
23. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635-641.
24. Said K. Hokusai-VTE: edoxaban for the treatment of venous thromboembolism. Glob Cardiol Sci Pract. 2013;2013(4):416-420.